Bifidobacterium animalis subspecies lactis engineered to produce mycosporin-like amino acids in colorectal cancer prevention. (January 2019)

• Record Type: Journal Article
• Authors: Bozkurt, Hüseyin Sancar; Quigley, Eamonn MM; Kara, Banu
• Is Part Of: SAGE open medicine. Volume 7(2019)
• Publication Date: 2019-01
• Subjects: Mycosporin-like amino acids -- Bifidobacterium -- genetic engineering -- colorectal cancer; Medicine -- Periodicals; 610.5
• DOI: 10.1177/2050312119825784
• Languages: English
• ISSNs: 2050-3121

Abstract

Colorectal cancer is the third most common cancer and the third leading cause of cancer-related death. The pathogensesis of colorectal cancer involves a multi-step and multi-factorial process. Disruption of the gut microbiota has been associated with gastrointestinal diseases such as colorectal cancer. The genus Bifidobacterium is considered an important component of the commensal microbiota and plays important roles in several homeostatic functions: immune, neurohormonal, and metabolic. Bifidobacterium animalis subsp. lactis is a well-documented probiotic within the species Bifidobacterium. Mycosporin-like amino acids are low molecular weight amino acids demonstrated to exert prebiotic effects and to modulate host immunity by regulating the proliferation and differentiation of intestinal epithelial cells, macrophages and lymphocytes, as well as cytokine production.Their modulation of the metabolism of the immune system and transcription factors could exert a beneficial effect on colorectal cancer. B. animalis does not produce mycosporin-like amino acids. If one could create a B. animalis –producing mycosporin-like amino acids via genetic open reading frame engineering it should exert more potent immuno-stimulatory properties and, thereby, become a potent strain-specific microbial based therapy in colorectal cancer prevention.